DLA Piper advised biotechnology company IMVIONIX Inc. on its acquisition of exclusive commercial rights to BEOVU®, an FDA-approved retinal therapy, in the US and Canada from Novartis. The acquisition marks IMVIONIX’s entry as a commercial-stage ophthalmology company.
BEOVU® is approved for the treatment of Neovascular (Wet) Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME), two leading causes of irreversible vision loss.
The DLA Piper deal team was led by Partners Lauren Murdza (Philadelphia) and James McGraw (Washington, DC) and Associate Shai Wood (Philadelphia), with support from Partners Andrew Gilbert (Short Hills/New York), Lisa Haile (San Diego), W. Kurtis Weaver (Boston), Christopher Mikson (Washington, DC/Philadelphia), and William Bartow, and Associate Andrew Dietrick (both Philadelphia).
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
